RBX7455 Oral Clostridium difficile Prevention

Rebiotix is leveraging it clinical and regulatory experience with RBX2660 to develop an oral Microbiota Restoration Therapy (MRT) targeted at Clostridium difficile (C. diff.) infection prevention.

About RBX7455

  • Oral MRT will enable easier application for repeat dosing
  • Lyophilized formulation
  • Room temperature stability
  • Broad spectrum gut microbiota
  • Master File submitted to the U.S. Food and Drug Administration
  • First human clinical study expected to begin enrollment in Q4 2016
RBX7455 Oral Clostridium difficile Prevention Rebiotix